Agenus Inc. Lawsuit Overview
Agenus Inc. is currently facing a securities class action lawsuit initiated by Levi & Korsinsky, LLP, on behalf of its investors. The law firm is notifying those affected by this case, underscoring the need for shareholders to be informed about their rights and potential actions they can take.
Understanding the Class Action
The lawsuit aims to recover losses for investors who suffered during the specified period due to alleged securities fraud. This fraud is claimed to have occurred between January 23, 2023, and July 17, 2024, where misleading information has been attributed to the company’s immuno-oncology products, particularly the combination therapy involving botensilimab and balstilimab.
Key Allegations in the Case
The allegations against Agenus indicate that the company and its executives made statements that were not only misleading but also false regarding the effectiveness of their therapies. This alleged misinformation led to inflated expectations regarding the clinical results and regulatory approvals of their products, which consequently misled investors about the true performance of the company.
Next Steps for Affected Investors
Investors who incurred losses during the defined time frame are encouraged to take action by November 5, 2024, to request the appointment as a lead plaintiff in the lawsuit. It’s vital to note that participating in the case does not necessitate taking up the role of a lead plaintiff, and investors can still claim their share of the recovery.
Engaging with Levi & Korsinsky
One of the significant advantages of engaging with Levi & Korsinsky is that there are no upfront costs for a class member wishing to participate in the lawsuit. If it is determined that the class action lawsuit is successful, compensation may be awarded without any out-of-pocket expenses to the investors involved.
Levi & Korsinsky's Track Record
With over two decades of experience in securities litigation, Levi & Korsinsky has successfully secured substantial compensation for shareholders. The firm’s prowess in navigating complex legal landscapes places it among the top contenders in the field, consistently recognized in the ISS Securities Class Action Services' Top 50 Report.
Contact Information
Agenus investors can reach out to Joseph E. Levi, Esq., for assistance regarding the lawsuit. The contact information for the firm is available for those who wish to discuss their situation or seek representation. The firm is situated at 33 Whitehall Street, 17th Floor, New York, NY 10004, and can be reached by telephone.
Frequently Asked Questions
What is the deadline for investors to act on this lawsuit?
The deadline to request appointment as lead plaintiff is November 5, 2024.
Who can participate in this class action?
Any shareholder of Agenus who incurred losses during the specified timeframe can participate.
What is the role of a lead plaintiff?
A lead plaintiff represents the interests of all class members in the lawsuit, but you do not need to be one to recover losses.
Are there any costs associated with joining the lawsuit?
No, there are no out-of-pocket costs for class members participating in the lawsuit.
Why is Levi & Korsinsky a reputable choice for this case?
They have a proven track record in securities litigation and have helped recover substantial amounts for shareholders.
